Can VIP Calm Chronic Inflammation? Here Is What We Know

Watch the full video on Rumble: https://rumble.com/v7i46mq-can-vip-calm-chronic-inflammation-here-is-what-we-know.html

If you've been dealing with inflammation that just won't settle down, and somewhere along the way somebody told you to look into VIP, this video is for you. VIP is a signal your nerves already make, your body clears it in about a minute, and the only thing it has ever been approved to treat is erectile dysfunction.

So before you spend money on it, you should understand the whole pathway it sits inside, because that is what tells you whether adding more of it from the outside makes any sense.

Start with the inflammation system itself, because it is simpler than it sounds.

Think about what happens when you cut your finger. The area gets red, it gets hot, it swells up. That's inflammation, and it's your immune system doing its job.

There are cells sitting in that tissue whose whole purpose is to sound the alarm, and they pour out chemical signals that say something is wrong here and send help, so more immune cells show up, blood flow climbs, and the area gets to work. Then when the job is done a second set of cells steps in and puts the brakes on, the alarm quiets, the swelling drains away, and you forget the cut ever happened.

That's basically the whole system. An alarm that turns on and a brake that turns it off.

Well, when inflammation won't settle, that's the system stuck with the alarm on. The brakes are not doing their job, and that is the problem you are actually trying to solve, whether it shows up in your joints, in your gut, or as fog you cannot shake.

Your nervous system is wired directly into that alarm and brake setup, and VIP, which stands for vasoactive intestinal peptide and is a small protein your nerves make in your gut, your lungs and your brain, is one of the signals your nerves use to talk to it.

When a nerve releases VIP right next to those alarm cells, it tells them to turn the volume down. Less alarm signal gets made, and at the same time VIP nudges the brake cells to do their work, which is why Delgado and colleagues in Nature Medicine described it as a nerve-derived message that pushes immune cells toward the quieting side.

This signal fires on a loop you never notice, and every time you eat a meal the VIP nerves in your gut switch on, which is part of how your gut handles the food you just swallowed.

It's a signal running constantly in your body right now, whether you're aware of it or not.

Now the detail that changes everything about how you should think about taking it. Your body uses VIP for roughly one minute, a nerve lets it go, the cells immediately next door read it, and then it is gone.

Your lungs are actually full of an enzyme that chops it up, and the people who measured this found half of it gone from the blood in about 60 seconds.

That tells you what VIP was built to be. It is a local message passed between neighbors, not a hormone circulating through your whole body looking for a target, which is exactly why every drug company that tried to turn it into a medicine ended up building longer-lasting copies or pumping it in through a continuous IV.

It also explains the first thing you feel when you take it from the outside, and it has nothing to do with your inflammation. Your blood vessels open, your face flushes, your pulse picks up, your blood pressure dips. The stand-down message to your immune cells is quiet and local. The blood vessel effect is loud and everywhere.

You'd expect more stand-down signal to always mean less inflammation, but that's not what the evidence shows. When Abad and colleagues bred mice that could not make VIP at all, those mice turned out to be almost completely protected from the mouse version of multiple sclerosis, and giving the signal back brought the disease back with it.

VIP docks onto two different receptor types on your cells and they pull in opposite directions, one calming things down, the other in the wrong setting helping immune cells travel to where the trouble is. Your body solves that by releasing tiny amounts in exactly the right spot at exactly the right moment, and a needle can't replicate that kind of precision because it floods every receptor you own at once.

So the question becomes whether that flood actually lowers inflammation in a human being, and the honest answer is that almost everything above was worked out in animals and in cells. In people, the measurement has happened exactly once.

20 people with an inflammatory lung disease breathed VIP for a month, and when Prasse and colleagues rinsed a sample out of those lungs, the immune cells in it were making less alarm signal and there were more brake cells present.

That's the human evidence that the mechanism works in a person.

20 people with no comparison group and it was measured in their lungs, not in their joints or their gut. For gut inflammation, for whole body inflammation, for brain fog, nobody has run the study. And the mold protocol that sends a lot of people looking for this peptide traces back to a single clinic's published series that nobody outside that clinic has tested.

The clinical research on VIP is not thin. It simply lives in a different corner of medicine than the one people searching for it expect.

The biggest trial ever run on it was during COVID. The NIH gave 461 people with failing lungs either VIP through an IV or they gave them a placebo and nobody knew who got which.

After 90 days, 38% of the people on VIP had died.

On placebo, that number was 36%. The monitoring board stopped the trial early because the two arms were landing in the same place, and this was continuous IV dosing in critically ill patients, meaning the drug was in the blood far longer than any at-home protocol achieves.

The picture flips entirely once you look at erectile dysfunction. VIP paired with a second drug worked in 75% of men against 12% on placebo across two trials of 171 men and 195 men, the numbers Dinsmore and colleagues reported in BJU International.

That's why it got approved for that and nothing else because that's where it works, through the blood vessels, which is the one thing the molecule does loudly and reliably.

There's a third result worth knowing. 21 people who get migraines got a VIP drip one day and saltwater another day without knowing which one was which, and in Rahmann's study, 15 of them got a migraine from the VIP, one got one from the saltwater.

So the strong human results sit in blood vessels, in erectile dysfunction, and in reliably triggering migraines. The inflammation story in people is 20 people and a lung rinse.

There is no slow build with this one. The flush arrives in minutes, your face reddens, your heart rate climbs, your blood pressure can dip, and in the people who were studied it settled back within a couple of hours.

That's the vasoactive part doing exactly what the name says.

After that nobody can tell you what to expect for inflammation, because the human timeline ends at that four week lung study. Inside my community I have one member who stacked it with two other peptides and says it was the main thing that cleared his brain fog, and another who is not sure it did anything at all.

And that's basically where the evidence sits.

The common side effects all trace back to blood vessels opening. In the NIH trial four things showed up more often on VIP than on placebo: loose stools, flushing, faster heart rate, and lower blood pressure, and all four got more common as the dose went up. Among men using the erectile dysfunction product, about one in five got facial flushing.

The diarrhea is VIP doing its gut job too well, because one of its normal duties, documented by Domschke back in 1978, is telling your bowel to pour fluid into itself.

What matters more are the risks that go beyond an upset stomach. If you get migraines, leave this peptide alone, because 15 out of 21 is a result and it's the clearest result VIP has.

Research: Prasse et al., PNAS, 2010 (PMID: 20442436); Rahmann et al., Cephalalgia, 2008 (PMID: 18254893); Abad et al., Journal of Immunology, 2010 (PMID: 20978211); Dinsmore et al., BJU International, 1999 (PMID: 10233493); Domschke et al., Gut, 1978 (PMID: 730072); Delgado et al., Nature Medicine, 2001 (PMID: 11329057).

References

Prasse et al., Proceedings of the National Academy of Sciences of the United States of America, 2010. PMID: 20442436. https://pubmed.ncbi.nlm.nih.gov/20442436/

Rahmann et al., Cephalalgia, 2008. PMID: 18254893. https://pubmed.ncbi.nlm.nih.gov/18254893/

Abad et al., Journal of Immunology, 2010. PMID: 20978211. https://pubmed.ncbi.nlm.nih.gov/20978211/

Dinsmore et al., BJU International, 1999. PMID: 10233493. https://pubmed.ncbi.nlm.nih.gov/10233493/

Domschke et al., Gut, 1978. PMID: 730072. https://pubmed.ncbi.nlm.nih.gov/730072/

Delgado et al., Nature Medicine, 2001. PMID: 11329057. https://pubmed.ncbi.nlm.nih.gov/11329057/